Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  decitabine
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 80 for your search:
Start Over
An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR017842, DACOGENMDS4013, Long-term treatment of Dacogen, NCT01400633
Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0358, NCT00398983
Phase III Randomized Study of Decitabine Versus Supportive Care in Patients With Advanced Myelodysplastic Syndromes
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SUPERGEN-D-0007, ABCCC-010303, NCT00043381
Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome
Phase: Phase III
Type: Treatment
Status: Closed
Age: 60 and over
Sponsor: Other
Protocol IDs: CDR0000256224, EORTC-06011, SUPERGEN-EORTC-06011, GMDSG-EORTC-06011, EudraCT-2005-002830, NCT00043134
Trial of Decitabine in Patients With Acute Myeloid Leukemia
Phase: Phase III
Type: Treatment
Status: Completed
Age: 65 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: DACO-016, NCT00260832
An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR015037, DACOGENMYE3001, NCT01026376
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Treatment
Status: Closed
Age: 70 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CYC682-12, NCT01303796
Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome
Phase: Phase III
Type: Natural history/Epidemiology
Status: Completed
Age: 20 to 70
Sponsor: Other
Protocol IDs: H-1012-015-342, NCT01409070
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 15 to 55
Sponsor: NCI, Other
Protocol IDs: DM94-064, P30CA016672, MDA-DM-94064, NCI-G96-0999, CDR0000065033, NCT00002831
Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 60 and under
Sponsor: NCI, Other
Protocol IDs: DM94-077, P30CA016672, MDA-DM-94077, NCI-G96-1000, CDR0000065034, NCT00002832
Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 06-054, MSKCC-06054, NCT00382200
Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 0704-07 IUCRO-0185, NCT00477386
Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCI 07-008, NCT00715793
LBH589 Plus Decitabine for Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 60 and over
Sponsor: Other
Protocol IDs: 08-0172 / 201012979, NCT00691938
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-0450, NCI-2010-01030, NCT00791271
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CASE2908, NCI-2010-00135, NCT01165996
Study of Sapacitabine in Acute Myeloid Leukemia (AML)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 70 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CYC682-11, NCT01211457
Phase II Study of Decitabine in Hormone-Refractory Stage D2 Prostate Cancer (Summary Last Modified 11/94)
Phase: Phase II
Type: Treatment
Status: Completed
Age: over 18
Sponsor:
Protocol IDs: NCI-94-C-0002A, NCI-CPB-332
Phase II Trial of 5-Aza-2'-deoxycytidine in Patients with Advanced Squamous Cell Carcinoma, Adenocarcinoma, and Large Cell Carcinoma of the Lung
Phase: Phase II
Type: Treatment
Status: Closed
Age: 75 and under
Sponsor:
Protocol IDs: EORTC-16851C
Phase II Chemotherapy with 5-AZA-2'-Deoxycytidine in Patients with Relapsed or Refractory Stage III/IV Hodgkin's Disease
Phase: Phase II
Type: Treatment
Status: Closed
Age: over 15
Sponsor:
Protocol IDs: EORTC-20861
Phase II Study of Chemotherapy with 5-Aza-2'-Deoxycytidine in Patients with Advanced Epithelial Cancer of the Ovary
Phase: Phase II
Type: Treatment
Status: Closed
Age: 70 and under
Sponsor:
Protocol IDs: EORTC-16851G
Start Over